Nanomedicines: exploring the past, present and future

Yvonne Perrie, Euan Ramsay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines. They offer a number of advantages in terms of stability, efficacy and off-target effects, but traditional manufacturing methods are labour-intensive, hard to reproduce and difficult to scale up. This has contributed to a widely-held perception in the pharmaceutical industry that nanomedicines are far from clinically practical. A new generation of microfluidic systems is helping to overcome these issues, allowing the rapid development and seamless scale-up of novel nanoparticles. This technology is transforming the development and manufacture of a range of nanoparticle formulations from a hit-and-miss affair into a standardised process, accelerating novel nanomedicines from the bench to the clinic.

LanguageEnglish
Pages17-22
Number of pages6
JournalDrug Discovery World
Volume18
Issue numberFall
Publication statusPublished - 1 Dec 2017

Fingerprint

Nanomedicine
Nanoparticles
Microfluidics
Drug Industry
Liposomes
Anti-Inflammatory Agents
Vaccines
Technology
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • microfluidics
  • nanomedicine
  • liposomes

Cite this

Perrie, Yvonne ; Ramsay, Euan. / Nanomedicines : exploring the past, present and future. In: Drug Discovery World. 2017 ; Vol. 18, No. Fall. pp. 17-22.
@article{48dbd565e5af4266b9c05e839d8e13f2,
title = "Nanomedicines: exploring the past, present and future",
abstract = "Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines. They offer a number of advantages in terms of stability, efficacy and off-target effects, but traditional manufacturing methods are labour-intensive, hard to reproduce and difficult to scale up. This has contributed to a widely-held perception in the pharmaceutical industry that nanomedicines are far from clinically practical. A new generation of microfluidic systems is helping to overcome these issues, allowing the rapid development and seamless scale-up of novel nanoparticles. This technology is transforming the development and manufacture of a range of nanoparticle formulations from a hit-and-miss affair into a standardised process, accelerating novel nanomedicines from the bench to the clinic.",
keywords = "microfluidics, nanomedicine, liposomes",
author = "Yvonne Perrie and Euan Ramsay",
year = "2017",
month = "12",
day = "1",
language = "English",
volume = "18",
pages = "17--22",
journal = "Drug Discovery World",
issn = "1469-4344",
publisher = "RJ Communications and Media Ltd.",
number = "Fall",

}

Nanomedicines : exploring the past, present and future. / Perrie, Yvonne; Ramsay, Euan.

In: Drug Discovery World, Vol. 18, No. Fall, 01.12.2017, p. 17-22.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nanomedicines

T2 - Drug Discovery World

AU - Perrie, Yvonne

AU - Ramsay, Euan

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines. They offer a number of advantages in terms of stability, efficacy and off-target effects, but traditional manufacturing methods are labour-intensive, hard to reproduce and difficult to scale up. This has contributed to a widely-held perception in the pharmaceutical industry that nanomedicines are far from clinically practical. A new generation of microfluidic systems is helping to overcome these issues, allowing the rapid development and seamless scale-up of novel nanoparticles. This technology is transforming the development and manufacture of a range of nanoparticle formulations from a hit-and-miss affair into a standardised process, accelerating novel nanomedicines from the bench to the clinic.

AB - Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines. They offer a number of advantages in terms of stability, efficacy and off-target effects, but traditional manufacturing methods are labour-intensive, hard to reproduce and difficult to scale up. This has contributed to a widely-held perception in the pharmaceutical industry that nanomedicines are far from clinically practical. A new generation of microfluidic systems is helping to overcome these issues, allowing the rapid development and seamless scale-up of novel nanoparticles. This technology is transforming the development and manufacture of a range of nanoparticle formulations from a hit-and-miss affair into a standardised process, accelerating novel nanomedicines from the bench to the clinic.

KW - microfluidics

KW - nanomedicine

KW - liposomes

UR - http://www.scopus.com/inward/record.url?scp=85051421929&partnerID=8YFLogxK

UR - https://www.ddw-online.com/drug-discovery/p320740-nanomedicines-exploring-the-pastpresent-and-future.html

M3 - Article

VL - 18

SP - 17

EP - 22

JO - Drug Discovery World

JF - Drug Discovery World

SN - 1469-4344

IS - Fall

ER -